NO943344D0 - MN-gen og -protein - Google Patents

MN-gen og -protein

Info

Publication number
NO943344D0
NO943344D0 NO943344A NO943344A NO943344D0 NO 943344 D0 NO943344 D0 NO 943344D0 NO 943344 A NO943344 A NO 943344A NO 943344 A NO943344 A NO 943344A NO 943344 D0 NO943344 D0 NO 943344D0
Authority
NO
Norway
Prior art keywords
gene
protein
Prior art date
Application number
NO943344A
Other languages
English (en)
Other versions
NO314191B1 (no
NO943344L (no
Inventor
Jan Zavada
Silvia Pastorekova
Jaromir Pastorek
Original Assignee
Ciba Corning Diagnostics Corp
Inst Of Virology Slovak Academ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25745325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO943344(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Corning Diagnostics Corp, Inst Of Virology Slovak Academ filed Critical Ciba Corning Diagnostics Corp
Publication of NO943344D0 publication Critical patent/NO943344D0/no
Publication of NO943344L publication Critical patent/NO943344L/no
Publication of NO314191B1 publication Critical patent/NO314191B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO19943344A 1992-03-11 1994-09-09 Sammensetning omfattende en nukleinsyresekvens som koder for MN-protein samt fremgangsmåte for fremstilling av disse, og anvendelse derav ivaksine og diagnostikk NO314191B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CS70992 1992-03-11
US07/964,589 US5387676A (en) 1992-03-11 1992-10-21 MN gene and protein
PCT/US1993/002024 WO1993018152A1 (en) 1992-03-11 1993-03-08 Mn gene and protein

Publications (3)

Publication Number Publication Date
NO943344D0 true NO943344D0 (no) 1994-09-09
NO943344L NO943344L (no) 1994-09-09
NO314191B1 NO314191B1 (no) 2003-02-10

Family

ID=25745325

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19943344A NO314191B1 (no) 1992-03-11 1994-09-09 Sammensetning omfattende en nukleinsyresekvens som koder for MN-protein samt fremgangsmåte for fremstilling av disse, og anvendelse derav ivaksine og diagnostikk

Country Status (8)

Country Link
US (5) US5387676A (no)
EP (1) EP0637336B1 (no)
JP (3) JP3755536B2 (no)
AU (1) AU669694B2 (no)
CA (1) CA2131826C (no)
DE (1) DE69325577T2 (no)
NO (1) NO314191B1 (no)
WO (1) WO1993018152A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6069242A (en) * 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5989838A (en) * 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US6093548A (en) * 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6027887A (en) * 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US6774117B1 (en) * 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
EP0763110B9 (en) * 1994-06-15 2005-09-14 Institute Of Virology Mn gene and protein
CA2192678C (en) * 1994-06-15 2010-12-14 Jan Zavada Mn gene and protein
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
US6087098A (en) * 1997-04-15 2000-07-11 The Trustees Of Columbia University In The City Of New York Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma
US7713704B1 (en) 1998-10-23 2010-05-11 Institute Of Virology Of The Slovak Academy Of Science MN gene and protein
US6403327B1 (en) 1999-08-05 2002-06-11 The Regents Of The University Of California Diagnostic method using expression of MN/CA9 protein in ASCUS Pap smears
US6379907B1 (en) 1999-08-05 2002-04-30 The Regents Of The University Of California Diagnostic method using expression of MN/CA9 protein in AGUS Pap smears
US7910691B2 (en) * 1999-10-22 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US20100135980A1 (en) * 2000-10-16 2010-06-03 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy
EP1733736B1 (en) 2001-02-07 2015-02-25 Wilex AG Method of producing recombinant antibodies against tumours
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
WO2002086089A2 (en) * 2001-04-23 2002-10-31 Quark Biotech, Inc. The 76a11 polypeptide and uses thereof
JP2005538682A (ja) * 2001-12-03 2005-12-22 アブジェニックス・インコーポレーテッド カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
US7910549B2 (en) 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
ATE509032T1 (de) 2002-02-13 2011-05-15 Ludwig Inst For Cancer Res Ltd Chimerizierte gm-csf antikörper
CA2477163C (en) * 2002-02-21 2010-07-27 Institute Of Virology Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes
SI3031910T1 (en) 2002-02-21 2018-05-31 Institute Of Virology Slovak Academy Of Sciences MN / CA IX-SPECIFIC MONOCLONIC PROTECTOR GENERATED FROM MN / CA- DEFROSTABLE MICE AND METHOD OF APPLICATION
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
WO2003089659A1 (en) * 2002-04-16 2003-10-30 The Regents Of The University Of California Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix
US20030232030A1 (en) * 2002-06-12 2003-12-18 L'oreal Compositions containing at least one oil structured with at least one silicone-polyamide polymer, and at least one gelling agent and methods of using the same
AU2003280442B2 (en) 2002-07-01 2009-02-05 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
US20090252738A1 (en) * 2002-08-23 2009-10-08 Novartis Vaccines And Diagnostics, Inc. Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
SI2594265T1 (sl) 2002-11-26 2016-03-31 Institute Of Virology Slovak Academy Of Sciences CA-IX specifični inhibitorji
EP1673630A4 (en) * 2003-10-16 2009-04-29 Inst Virology MN / AC IX AND PROGNOSIS OF CANCER
US7482129B2 (en) * 2004-05-04 2009-01-27 Institute Of Virology, Slovak Academy Of Sciences MN/CA IX/CA9 and Renal Cancer Prognosis
EP1763367A2 (en) 2004-07-02 2007-03-21 Wilex AG Improved adjuvant therapy of g250-expressing tumors
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20080038251A1 (en) * 2006-03-20 2008-02-14 Silvia Pastorekova MN/CA IX and MAPK inhibition
US20100056611A1 (en) * 2006-10-12 2010-03-04 Jaromir Pastorek MN/CA9 Splice Variants
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
US8097423B2 (en) * 2007-07-30 2012-01-17 Institute Of Virology MN/CA IX and breast cancer therapy
US7919006B2 (en) * 2007-10-31 2011-04-05 Freescale Semiconductor, Inc. Method of anti-stiction dimple formation under MEMS
WO2009056342A1 (en) 2007-11-02 2009-05-07 Wilex Ag Binding epitopes for g250 antibody
WO2009059281A1 (en) * 2007-11-02 2009-05-07 Health Research Inc. Compositions and methods for using ca9 protein to stimulate an immune response
EP2477661B1 (en) 2009-09-15 2017-06-14 Wilex AG Selective detection of bone metastases in renal clear cell carcinoma
US8993347B2 (en) * 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
JP2016511766A (ja) 2013-02-22 2016-04-21 ウィレックス・アーゲー Ｃａｉｘ階層化に基づく癌治療
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10252231B2 (en) 2014-10-31 2019-04-09 Massachusetts Institute Of Technology Compositions and methods for forming emulsions
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
IL292413A (en) 2019-11-05 2022-06-01 Mabpro A S Humanized anti-ca ix antibodies and methods of using them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
CA2192678C (en) * 1994-06-15 2010-12-14 Jan Zavada Mn gene and protein

Also Published As

Publication number Publication date
JP4624900B2 (ja) 2011-02-02
US7816496B2 (en) 2010-10-19
AU669694B2 (en) 1996-06-20
DE69325577D1 (de) 1999-08-12
JP4865896B2 (ja) 2012-02-01
US6004535A (en) 1999-12-21
JP3755536B2 (ja) 2006-03-15
AU3792793A (en) 1993-10-05
CA2131826A1 (en) 1993-09-16
US6051226A (en) 2000-04-18
US20070255043A1 (en) 2007-11-01
JPH07508160A (ja) 1995-09-14
US5387676A (en) 1995-02-07
NO314191B1 (no) 2003-02-10
US20080221309A1 (en) 2008-09-11
EP0637336A1 (en) 1995-02-08
CA2131826C (en) 2000-05-16
JP2006083179A (ja) 2006-03-30
EP0637336B1 (en) 1999-07-07
JP2011036254A (ja) 2011-02-24
DE69325577T2 (de) 2000-01-13
WO1993018152A1 (en) 1993-09-16
NO943344L (no) 1994-09-09

Similar Documents

Publication Publication Date Title
NO943344D0 (no) MN-gen og -protein
DK91192D0 (da) Protein
DE69333042D1 (de) Protein l und entsprechenden proteinhybriden
NO934477D0 (no) PEG hydrazon- og PEG oksim-bindingdannende reagenser og protein-derivater derav
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
AU2861695A (en) Mn gene and protein
DE59407063D1 (de) Deodorierende zubereitungen
DK132892D0 (da) Proteiner
GB9516059D0 (en) Novel genes and proteins
DE69429514D1 (de) Antiparasitäre präparate
KR950700316A (ko) 재조합 지베렐린 디엔에이(dna) 및 이들의 사용 방법(recombinant gibberellin dna and uses thereof)
DE4396174T1 (de) Entstapel- und Beschickungsanlage
ZA918423B (en) Proteins and nucleic acids.
EP0766693A4 (en) NOVEL GENES AND PROTEINS OF PEST PROTEASES
KR960010685A (ko) 펩티드 및 그 용도
ITMI921571A1 (it) Azaciclo e azabiciclo alchiliden idrossilamine
FI1031U1 (fi) En troakar
FI952108A0 (fi) Fibronnektiiniä sitova proteiini sekä sen valmistaminen
DE59302218D1 (de) Krempel- und Kardenantrieb
BR9202070A (pt) Demulsificador e coagualdor polieletrolito cationico
GB9310227D0 (en) Protein and dna
DE69326230T2 (de) Insertionselemente und amplifizierbare nukleinsäuren
PT8772U (pt) Recipiente-embalagem e brinquedo
BR1100734A (pt) Proteìna; proteìna ostogênica; e proteìna isolada
DE59307832D1 (de) Misch- und fördergerät

Legal Events

Date Code Title Description
MK1K Patent expired